好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Eleven Month Progression Free Survival on Vemurafenib Monotherapy in a Patient with Recurrent and Metastatic BRAF V600E Mutated Glioblastoma WHO Grade IV
Neuro-oncology
P6 - (-)
130
Authors/Disclosures
Kanita Beba Abadal, MD (University of South Florida College of Medicine)
PRESENTER 		Dr. Beba has nothing to disclose.
No disclosure on file
Anthony T. Yachnis, MD (University of Florida College of Medicine) No disclosure on file
No disclosure on file
Ashley P. Ghiaseddin, MD, FAAN (University of Florida) Dr. Ghiaseddin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neosoma. Dr. Ghiaseddin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Servier. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Monteris Medical. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Deciphera. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global Consulting. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Telix. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nuvation Bio. Dr. Ghiaseddin has or had stock in CRISPR Therapeutics AG.